Helle Holst

Senior Director
Novo Nordisk A/S

Presentation(s):

• PB0657 - Up to 6 years of once-weekly prophylactic dosing of nonacog beta pegol (N9-GP) was associated with high adherence, with a low incidence of spontaneous bleeds in children with hemophilia B

  Monday, July 11, 2022
  6:30 PM – 7:30 PM